Bavarian Nordic A/S (CPH:BAVA)
Denmark
· Delayed Price · Currency is DKK | Market Cap | 14.04B |
| Revenue (ttm) | 6.23B |
| Net Income (ttm) | 1.32B |
| Shares Out | 77.84M |
| EPS (ttm) | 16.62 |
| PE Ratio | 10.86 |
| Forward PE | 11.72 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 187,008 |
| Average Volume | 350,614 |
| Open | 179.75 |
| Previous Close | 179.50 |
| Day's Range | 178.50 - 182.15 |
| 52-Week Range | 123.30 - 300.00 |
| Beta | 1.21 |
| RSI | 68.49 |
| Earnings Date | May 9, 2025 |
About Bavarian Nordic
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the Unite... [Read more]
Financial Performance
In 2024, Bavarian Nordic's revenue was 5.72 billion, a decrease of -19.06% compared to the previous year's 7.06 billion. Earnings were 987.98 million, a decrease of -33.03%.
Financial StatementsNews
Bavarian Nordic A/S (BVNKF) Q1 2025 Earnings Call Transcript
Bavarian Nordic A/S (OTCPK:BVNKF) Q1 2025 Earnings Conference Call May 9, 2025 8:00 AM ET Company Participants Rolf Sass Sorensen - Head, Investor Relations Paul Chaplin - Chief Executive Officer Henr...
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
COPENHAGEN, Denmark, May 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company's shares/related securities by persons holding manager...
Bavarian Nordic A/S 2025 Q1 - Results - Earnings Call Presentation
Bavarian Nordic A/S reports interim Q1 results
Bavarian Nordic Announces Interim Results for the First Three Months of 2025
COPENHAGEN, Denmark , May 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2025.
Bavarian Nordic Awarded Contract Options from the U.S. Government for Production and Supply of Freeze-dried Smallpox/Mpox Vaccines
COPENHAGEN, Denmark, May 6, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Pre...
Bavarian Nordic Receives Marketing Authorization for Chikungunya Vaccine for Persons Aged 12 and Older in the United Kingdom
COPENHAGEN, Denmark, May 2, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in the Uni...
Bavarian Nordic's Chikungunya Vaccine Receives Recommendation from U.S. CDC's Advisory Committee on Immunization Practices (ACIP)
COPENHAGEN, Denmark, April 16, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACI...
Correction: Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S
COPENHAGEN, Denmark, April 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2024 was adopted. The Board of Directors' p...
Resolutions of the Annual General Meeting 2025 of Bavarian Nordic A/S
COPENHAGEN, Denmark, April 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2024 was adopted. The Board of Directors' p...
Bavarian Nordic Trading At Great Value Levels With Upbeat 2025 Outlook
BVNKF now expects margin improvements from rabies/TBE vaccine production transfers to Denmark, starting in 2025. Also, their recently FDA-approved freeze-dried Jynneos vaccine and EU/US-approved chiku...
Pharma tariff relief likely short-lived with sector-specific duties on the horizon
Pharmaceutical companies breathed a sigh of relief Wednesday after U.S. President Donald Trump revealed that they would not be subject to reciprocal tariffs — but that reprieve could prove fleeting. T...
US FDA approves freeze-dried version of Bavarian Nordic's mpox, smallpox vaccine
Denmark's Bavarian Nordic said on Monday the U.S. Food and Drug Administration has approved a freeze-dried formulation of its mpox and smallpox vaccine.
Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine
COPENHAGEN, Denmark, March 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the U.S. Food and Drug Administration (FDA) has approved the freeze-dried formulation of JYNNEOS® (Smallpox a...
Widely used drugs on US imports list from Europe
Widely used prescription medicines could get caught up in the Trump administration's tariff trade wars and EU retaliation.
Bavarian Nordic A/S – Notice Convening Annual General Meeting
COPENHAGEN, Denmark, March 12, 2025 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual General Meeting to be held on
Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and Older
COPENHAGEN, Denmark, March 7, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has validated the marketing authorization ap...
Bavarian Nordic A/S (BVNKF) Q4 2024 Earnings Call Transcript
Bavarian Nordic A/S (OTCPK:BVNKF) Q4 2024 Earnings Conference Call March 5, 2025 8:00 AM ETCompany ParticipantsRolf Sass Sorensen - Head, Investor...
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
COPENHAGEN, Denmark, March 5, 2025 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company's shares/related securities by persons holding manag...
Bavarian Nordic Publishes Annual Report 2024
Audited results confirm full-year revenue of DKK 5,716 million and EBITDA of DKK 1,603 million. Two new early-stage pipeline programs, Lyme disease and Epstein-Barr Virus (EBV), introduced.
Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older
COPENHAGEN, Denmark, February 28, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the European Commission has granted marketing authorization in Europe for VIMKUNYA® for active immunizatio...
Biological E in strategic pact with Danish co Bavarian Nordic to manufacture Chikungunya vax for global access
Hyderabad: Biopharma player Biological E (BE) entered into a strategic partnership with Danish vaccine maker Bavarian Nordic to manufacture the latter.
Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine
COPENHAGEN, Denmark, February 25, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced a strategic partnership with Biological E. Limited (BE) to expand access to Bavarian Nordic's chikungunya vacci...
Bavarian Nordic Receives U.S. FDA Approval of Chikungunya Vaccine for Persons Aged 12 and Older
COPENHAGEN, Denmark, February 14, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Food and Drug Administration (FDA) has approved VIMKUNYA™ (Chikungunya Vaccine, Recombinant) for ...
Bavarian Nordic Reports Preliminary 2024 Financial Results in Line with Upgraded Guidance and Guides for 2025
COPENHAGEN, Denmark, February 3, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced preliminary, unaudited financial results for 2024 and provided its financial guidance for 2025.